NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer.

Valentina GambardellaFrancisco Gimeno-ValienteNoelia TarazonaCarolina Martinez-CiarpagliniDesamparados RodaTania FleitasPablo TolosaJuan Miguel CejalvoMarisol Huerta Susana RosellóJosefa CastilloAndres Cervantes

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

NRF2 through the PI3K/AKT/mTOR/RPS6 pathway could be a potential effector of resistance to anti-HER2 drugs in our models. RPS6 inhibition decreases NRF2 expression and restores sensitivity in HER2-amplified gastric cancer in vitro and in vivo. High NRF2 expression in gastric cancer patients predicts resistance to treatment. RPS6 and NRF2 inhibition could prevent resistance to anti-HER2 drugs.

Keyphrases

oxidative stress
poor prognosis
risk assessment
long non coding rna
drug induced
climate change
replacement therapy